iSpecimen (NASDAQ:ISPC) Stock Price Down 2.9% – Here’s What Happened

iSpecimen Inc. (NASDAQ:ISPC)’s stock price traded down 2.9% on Tuesday . The company traded as low as $0.36 and last traded at $0.4084. 292,274 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 532,282 shares. The stock had previously closed at $0.4208.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ISPC. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research note on Wednesday, October 8th. Wall Street Zen raised iSpecimen to a “sell” rating in a report on Saturday, September 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

iSpecimen Stock Performance

The company’s fifty day simple moving average is $0.64 and its two-hundred day simple moving average is $0.96. The company has a market capitalization of $3.99 million, a price-to-earnings ratio of -0.05 and a beta of 1.80.

iSpecimen (NASDAQ:ISPC) last issued its quarterly earnings results on Monday, November 17th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($3.80) by $3.32. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $3.33 million. iSpecimen had a negative net margin of 343.86% and a negative return on equity of 531.78%.

Institutional Investors Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is currently owned by institutional investors and hedge funds.

iSpecimen Company Profile

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.